REGN News and Press, Regeneron Pharmaceuticals Inc. From 05/14/24

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell ...

2024-05-08 15:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-08 08:15:41 ET Regeneron ( NASDAQ: REGN ) announced Wednesday that a child who received its gene therapy candidate DB-OTO improved hearing to normal levels within 24 weeks in a Phase 1/2 trial for genetically linked deafness.... Read the full article on Seeking Alpha ...

2024-05-07 09:01:37 ET Apple ( NASDAQ: AAPL ) recently updated its capital return plan by adding a $110B to its buyback program. According to data highlighted by Mizuho, this massive buyback program is larger than 84% of the stocks that sit inside the S&P 500.... Read ...

2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...

2024-05-05 15:10:28 ET More on the markets S&P 500 1%+ Gaps Higher SPY: Don't Buy The Dip Just Yet Rate Hike Unlikely: Expect S&P 500 To Rally To New All-Time Highs Data Insight: April's jobs report was biggest disappointment in at least 2 years ...

2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte

2024-05-04 09:13:02 ET Summary Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide. These comments and previous phase 2 data point to the increasing possibility of Amgen becoming a real contender in the rapidly expa...

2024-05-03 15:00:00 ET More on the markets My Current View Of The Market: May 2024 Edition (Technical Analysis) SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish 'Sell in May and go away': Does it apply in 2024? ...